UNBS5162 is a naphthalimide that antagonizes the expression of CXCL chemokines. In vitro exposure of PC-3 prostate cancer cells to 1 µM UNBS5162 for five successive days was shown to decrease the expression of proangiogenic CXCL chemokines. UNBS5162 also demonstrates antiangiogenic properties in vivo in an orthotopic PC-3 model.